Stephen Ma
Directeur Financier/CFO chez SCILEX HOLDING COMPANY
Fortune : 12 175 $ au 30/04/2024
Profil
Stephen Ma is currently working as the Secretary, Chief Financial Officer & Senior VP at Scilex Holding Co. He previously worked as the Director-Finance & Operations at Anwita Biosciences, Inc. Mr. Ma has an undergraduate and graduate degree from San Jose State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SCILEX HOLDING COMPANY
0,01% | 17/05/2024 | 14 140 ( 0,01% ) | 12 175 $ | 30/04/2024 |
Postes actifs de Stephen Ma
| Sociétés | Poste | Début |
|---|---|---|
| SCILEX HOLDING COMPANY | Directeur Financier/CFO | 22/09/2023 |
Anciens postes connus de Stephen Ma
| Sociétés | Poste | Fin |
|---|---|---|
Anwita Biosciences, Inc.
 Anwita Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers. | Directeur Financier/CFO | 01/01/2022 |
Formation de Stephen Ma
| San Jose State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCILEX HOLDING COMPANY | Health Technology |
| Entreprise privées | 1 |
|---|---|
Anwita Biosciences, Inc.
Anwita Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company located in the US. Anwita's lead product, exenokine-21, has been accepted by China NMPA and the US FDA to initiate clinical studies. The American company specializes in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Anwita's core technology integrates structure-guided accukine cytokine evolution and accubody discovery of full spectrum nanobodies and antibodies, enabling the development of fully optimized cytokine fusions with superior therapeutic potential, favorable safety profile, and great development ability. The private company's unique product portfolio includes half-live extended exenokines, immune cell- or tumor cell-targeting mableukines, and bi-functional duoleukins. The company is also developing other cytokine-based therapeutics and antibody drug conjugates for the potential treatment of various cancers. | Health Technology |
